Brokers Offer Predictions for ALX Oncology FY2029 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for ALX Oncology in a research note issued on Friday, January 24th. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.63 per share for the year. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

ALXO has been the subject of a number of other research reports. Jefferies Financial Group downgraded ALX Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $12.00 to $2.00 in a report on Thursday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Friday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $3.50.

ALX Oncology Price Performance

ALXO opened at $1.52 on Monday. The stock has a fifty day simple moving average of $1.62 and a two-hundred day simple moving average of $2.36. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The company has a market cap of $79.91 million, a price-to-earnings ratio of -0.51 and a beta of 0.98. ALX Oncology has a 12-month low of $1.19 and a 12-month high of $17.83.

Institutional Investors Weigh In On ALX Oncology

A number of large investors have recently made changes to their positions in the company. Barclays PLC grew its stake in shares of ALX Oncology by 243.6% during the 3rd quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after purchasing an additional 42,185 shares during the period. XTX Topco Ltd bought a new position in shares of ALX Oncology during the 3rd quarter valued at approximately $578,000. Wellington Management Group LLP grew its stake in shares of ALX Oncology by 15.2% during the 3rd quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock valued at $305,000 after acquiring an additional 22,114 shares during the period. Verition Fund Management LLC grew its stake in shares of ALX Oncology by 308.4% during the 3rd quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock valued at $242,000 after acquiring an additional 100,454 shares during the period. Finally, Walleye Capital LLC boosted its stake in ALX Oncology by 110.3% in the 3rd quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock worth $420,000 after purchasing an additional 121,113 shares during the period. 97.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Rekha Hemrajani purchased 30,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average cost of $1.55 per share, for a total transaction of $46,500.00. Following the purchase, the director now directly owns 33,000 shares in the company, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders sold 14,443 shares of company stock valued at $23,309. 33.40% of the stock is owned by insiders.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.